Testosterone 1100 ng/dL — when high T isn't natural
A total testosterone reading of 1100 ng/dL in an adult male sits above the 95th percentile of population data — fewer than 5% of healthy men ever produce that endogenously. In the absence of a rare androgen-secreting tumour, persistent levels at this magnitude almost universally indicate exogenous androgen administration (TRT, anabolic steroid use, or supplemental DHEA at high doses). The research literature on supraphysiologic testosterone is clear: while short-term effects on body composition and mood are well-documented, sustained levels above ~1000 ng/dL are associated with reduced HDL, elevated haematocrit (clotting risk), suppressed LH and FSH (testicular atrophy and impaired fertility), increased aromatisation to oestradiol, and prostate hyperplasia.
Reference ranges
| Population mean — 30s male | ~530-600 ng/dL |
| Standard reference upper bound | ~916 ng/dL |
| Population 95th percentile | ~1000 ng/dL |
| TRT supraphysiologic | 1000 – 1500 ng/dL |
| Anabolic-steroid territory | > 1500 ng/dL |
What this marker measures
Total testosterone measures all circulating testosterone including SHBG-bound, albumin-bound, and free fractions. Endogenous testicular production is tightly regulated by the hypothalamic-pituitary-gonadal axis — LH stimulates Leydig-cell production, and circulating testosterone provides negative feedback. The system normally clamps total T in the 200-1000 ng/dL range; producing more requires either a tumour or an exogenous source bypassing the feedback loop.
Why might it be elevated?
- ·Exogenous testosterone (TRT, supraphysiologic dose)
- ·Anabolic steroid use
- ·Recent injection within 1-3 days (transient peak)
- ·Adrenal androgen-secreting tumour (rare)
- ·Leydig-cell tumour (very rare)
- ·Congenital adrenal hyperplasia (rare; usually presents in childhood)
- ·High-dose DHEA supplementation (modest effect)
Why might it be low?
- ·Primary hypogonadism (testicular failure — high LH)
- ·Secondary hypogonadism (pituitary / hypothalamic — low LH)
- ·Age-related decline
- ·Visceral adiposity
- ·Anabolic steroid suppression of natural production
FAQ
What's the safe upper bound for TRT?+
Most clinical TRT protocols target 700-900 ng/dL — within the high end of the normal range, where the benefit/risk ratio is favourable. Above 1000 ng/dL, the side-effect profile (haematocrit, lipids, oestradiol elevation, fertility) starts dominating in trial reports. Clinical decisions should involve an endocrinologist; this is research-context information.
Why does my LH come back near zero on TRT?+
Because exogenous testosterone provides negative feedback to the pituitary, suppressing LH (and FSH) release. This is the mechanism of TRT-induced testicular atrophy and infertility. Strategies to preserve testicular function during TRT (hCG, enclomiphene) are research areas.
This page describes biomarker research and reference ranges for self-tracking and research-context discussion only. It is not medical advice, not a diagnosis, and not a substitute for a qualified physician. Take any concerns about your health to a clinician.
Have your own panel? Read it next to the standard reference ranges with our free analyse tool.
Analyse my blood work →- BiomarkerDHEA-S 80 µg/dL
Dehydroepiandrosterone sulphate at 80 µg/dL in a man in his 40s is below the typical age-matched range. What DHEA-S measures, why the literature treats it as a global endocrine marker, and what its decline means.
- BiomarkerTotal T 450 ng/dL
Total testosterone of 450 ng/dL in a 35-year-old man is technically inside the standard reference range but well below the age-matched mean. What the number means without free T and SHBG context — and what a deeper read tells you.
- BiomarkerAM cortisol elevated
Morning serum cortisol above the standard reference range is associated in the research literature with chronic stress, sleep disruption, and metabolic dysregulation — the question is which.
- ResearchTesamorelin 10 mg
Tesamorelin is an approved GHRH analogue. The research-grade form is used widely in GH-axis, lipid-metabolism, and hepatic-fat research.
- GlossaryGHRH
Growth hormone-releasing hormone, the hypothalamic peptide that triggers GH release.
- ResearchIpamorelin 10 mg
Ipamorelin is a selective ghrelin-receptor (GHSR) agonist. One of the cleanest pharmacological profiles in the growth-hormone-secretagogue class.